Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.05−0.23 (-3.16%)
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Precision BioSciences cash
Cash and short-term investments held at the end of each period.
Precision BioSciences's cash was $87.55M at Jun 30, 2026. For fiscal 2025 it was $115.59M, up 6.2% from the year before. The highest annual figure on record is $189.58M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.59M | +6.2% |
| FY2024 | Dec 31, 2024 | $108.88M | -6.7% |
| FY2023 | Dec 31, 2023 | $116.68M | -38.5% |
| FY2022 | Dec 31, 2022 | $189.58M | +32.0% |
| FY2021 | Dec 31, 2021 | $143.66M | +60.0% |
| FY2020 | Dec 31, 2020 | $89.80M | -50.4% |
| FY2019 | Dec 31, 2019 | $180.89M | +75.3% |
| FY2018 | Dec 31, 2018 | $103.19M | +64.3% |
| FY2017 | Dec 31, 2017 | $62.80M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $87.55M | +40.7% |
| Q1 FY2026 | Mar 31, 2026 | $101.18M | +31.0% |
| Q4 FY2025 | Dec 31, 2025 | $115.59M | +6.2% |
| Q3 FY2025 | Sep 30, 2025 | $44.87M | -55.7% |
| Q2 FY2025 | Jun 30, 2025 | $62.24M | -49.6% |
| Q1 FY2025 | Mar 31, 2025 | $77.22M | -43.9% |
| Q4 FY2024 | Dec 31, 2024 | $108.88M | -6.7% |
| Q3 FY2024 | Sep 30, 2024 | $101.20M | -17.2% |
| Q2 FY2024 | Jun 30, 2024 | $123.57M | -10.3% |
| Q1 FY2024 | Mar 31, 2024 | $137.77M | -12.9% |
| Q4 FY2023 | Dec 31, 2023 | $116.68M | -38.5% |
| Q3 FY2023 | Sep 30, 2023 | $122.23M | -42.4% |
| Q2 FY2023 | Jun 30, 2023 | $137.79M | -25.2% |
| Q1 FY2023 | Mar 31, 2023 | $158.13M | +36.1% |
| Q4 FY2022 | Dec 31, 2022 | $189.58M | +32.0% |
| Q3 FY2022 | Sep 30, 2022 | $212.05M | +32.1% |
| Q2 FY2022 | Jun 30, 2022 | $184.14M | +5.9% |
| Q1 FY2022 | Mar 31, 2022 | $116.22M | -39.9% |
| Q4 FY2021 | Dec 31, 2021 | $143.66M | +60.0% |
| Q3 FY2021 | Sep 30, 2021 | $160.47M | +54.1% |
| Q2 FY2021 | Jun 30, 2021 | $173.94M | +37.1% |
| Q1 FY2021 | Mar 31, 2021 | $193.46M | +25.5% |
| Q4 FY2020 | Dec 31, 2020 | $89.80M | -50.4% |
| Q3 FY2020 | Sep 30, 2020 | $104.15M | -49.5% |
| Q2 FY2020 | Jun 30, 2020 | $126.89M | -43.9% |
| Q1 FY2020 | Mar 31, 2020 | $154.19M | +32.4% |
| Q4 FY2019 | Dec 31, 2019 | $180.89M | +75.3% |
| Q3 FY2019 | Sep 30, 2019 | $206.27M | +61.7% |
| Q2 FY2019 | Jun 30, 2019 | $226.10M | +80.4% |
| Q1 FY2019 | Mar 31, 2019 | $116.50M | +144.0% |
| Q4 FY2018 | Dec 31, 2018 | $103.19M | +64.3% |
| Q3 FY2018 | Sep 30, 2018 | $127.57M | – |
| Q2 FY2018 | Jun 30, 2018 | $125.34M | – |
| Q1 FY2018 | Mar 31, 2018 | $47.75M | – |
| Q4 FY2017 | Dec 31, 2017 | $62.80M | – |
See a number that looks wrong?